A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds? Author's response

Expert Opin Drug Saf. 2013 Sep;12(5):794-5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Benzoates / adverse effects*
  • Deferasirox
  • Humans
  • Iron Chelating Agents / adverse effects*
  • Patient Safety*
  • Triazoles / adverse effects*

Substances

  • Benzoates
  • Iron Chelating Agents
  • Triazoles
  • Deferasirox